{"id":1240,"date":"2023-01-10T16:16:25","date_gmt":"2023-01-10T16:16:25","guid":{"rendered":"https:\/\/www.americanconference.com\/controlled-substances\/?page_id=1240"},"modified":"2026-10-09T14:52:49","modified_gmt":"2026-10-09T14:52:49","slug":"overview","status":"publish","type":"page","link":"https:\/\/www.americanconference.com\/controlled-substances\/","title":{"rendered":"Overview"},"content":{"rendered":"<!-- GLOBAL STYLES -->\r\n<style>\r\n:root {\r\n\t--light-grey: #f5f5f5;\r\n\t--dark-grey: #121212; \/* attendees background; fold background *\/\r\n\t--color-a: #4D226B; \/* news background; stats background; topic icons; testimonial spotlight background *\/\r\n\t--color-b: #51609F; \/* attendee icons; testimonial stars *\/\r\n\t--textcolor-a: #F5F5F5; \/* text color for dark backgrounds *\/\r\n\t--textcolor-b: rgba(36, 36, 36, 0.8); \/* secondary text (speaker details, topic descrips) *\/\r\n\t--textcolor-c: rgba(245, 245, 245, 0.8); \/* secondary text for dark backgrounds *\/\r\n\t--bordercolor-a: rgba(245, 245, 245, 0.15); \/* border for dark backgrounds *\/\r\n\t--bordercolor-b: rgba(36, 36, 36, 0.15); \/* border *\/\r\n}\r\n.page-template-page-event-overview .content-event-page .sub-site-content-event-home .body-content p:last-child { margin-bottom: 24px; !important; }\r\n.content-event-page .sub-site-content-event-home .cta-content .cta-block-row { background-color: var(--color-a) !important; padding: 84px 0 120px !important; }\r\n.body-content a.mainlink { font-size: 14px; letter-spacing: 0.7px; font-weight: bold; text-transform: uppercase; text-decoration: underline; outline: none; color: #242424; }\r\n.body-content h2 { margin: 0 0 20px !important; padding-top: 11px !important; }\r\n.body-content h3 { margin-bottom: 23px !important; }\r\n.body-content h4 { margin-bottom: 12px !important; }\r\n.body-content h5 { margin-bottom: 12px !important; font-size: 16px !important; line-height: 24px !important; }\r\n.body-content hr { border-top: 1px solid var(--bordercolor-b); }\r\n\/* Mobile *\/\r\n@media (min-width: 320px) {\r\n\t#news-component, #featured-component, #attend-component, #networking-component, #fold-component, #alert-component { padding: 48px 0 72px; }\r\n\t.body-content hr { margin: 59px 0 48px; }\r\n}\r\n\/* Laptop *\/\r\n@media (min-width: 1024px) {\r\n\t#news-component, #featured-component, #attend-component, #networking-component, #fold-component, #alert-component { padding: 60px 0 84px; }\r\n}\r\n\/* Desktop *\/\r\n@media (min-width: 1280px) {\r\n\t#news-component, #featured-component, #attend-component, #networking-component, #fold-component, #alert-component { padding: 72px 0 108px; }\r\n\t.body-content hr { margin: 71px 0 60px; }\r\n}\r\n\/* Extra Large desktop *\/\r\n@media (min-width: 1536px) {\r\n\t#news-component, #featured-component, #attend-component, #networking-component, #fold-component, #alert-component { padding: 84px 0 120px; }\r\n}\r\n<\/style>\r\n\r\n\r\n\r\n<!-- #2 NEWS START -->\r\n<style>\r\n#news-component { background-color: var(--color-a); padding: 48px 0; }\r\n#news-component .news-cell { display: flex; margin-bottom: 24px !important; }\r\n#news-component h3, #news-component p, #news-component ol li, #news-component ul li, #news-component a { color: var(--textcolor-a) !important; }\r\n#news-component p, #news-component ol li, #news-component ul li { margin-bottom: 12px !important; font-size: 14px; line-height: 24px !important; }\r\n#news-component ol, #news-component ul { padding-left: 16px; }\r\n#news-component a { margin-bottom: 0 !important; outline: none; text-transform: uppercase; font-weight: bold; font-size: 12px; letter-spacing: 0.7px; line-height: 24px !important; }\r\n#news-component .news-cell img { margin-left: 24px; aspect-ratio: 1 \/ 1; }\r\n\/* Mobile *\/\r\n@media (min-width: 320px) {\r\n\t#news-component { padding: 48px 0; }\r\n\t#news-component h3 { margin-bottom: 0 !important; }\r\n\t#news-component .news-cell { padding: 24px 0 0 0; border-left: 0; border-top: 1px solid var(--bordercolor-a); }\r\n\t#news-component .news-cell img { display: none !important; }\r\n}\r\n\/* Tablet *\/\r\n@media (min-width: 768px) {\r\n\t#news-component h3 { margin-bottom: 23px !important; }\r\n\t#news-component .news-cell { padding: 0 0 0 24px; border-left: 1px solid var(--bordercolor-a); border-top: 0; }\r\n\t#news-component .news-cell img { display: inline !important; width: 72px; height: 72px; }\r\n}\r\n\/* Laptop *\/\r\n@media (min-width: 1024px) {\r\n\t#news-component .news-cell img { width: 96px; height: 96px; }\r\n}\r\n\/* Desktop *\/\r\n@media (min-width: 1280px) {\r\n\t#news-component .news-cell img { width: 120px; height: 120px; }\r\n}\r\n<\/style>\r\n<div class=\"row\" id=\"news-component\">\r\n<div class=\"container\">\r\n<div class=\"row\">\r\n<div class=\"col-xxxs-12 col-sm-12 col-md-2 col-lg-2 col-xl-2\">\r\n\t<h3>Latest News &amp;&nbsp;Updates<\/h3>\r\n<\/div>\r\n<div class=\"col-xxxs-12 col-sm-6 col-md-5 col-lg-5 col-xl-5\">\r\n\t<div class=\"news-cell\">\r\n\t\t<div>\r\n\t\t\t<p><strong>NEW THIS YEAR &mdash; Life Sciences Enforcement Operations LAB: Building the First <span style=\"white-space: nowrap;\">72-Hour<\/span> Response to FDA, DEA, DOJ and State Scrutiny<\/strong><\/p>\r\n\t\t\t<p>February 3, 2027 &bull; 10am&ndash;4pm<\/p>\r\n\t\t\t<a href=\".\/workshops\/life-sciences-enforcement-operations-lab\/\">Learn More<\/a>\t\t\r\n\t\t<\/div>\r\n\t<\/div>\r\n<\/div>\r\n<div class=\"col-xxxs-12 col-sm-6 col-md-5 col-lg-5 col-xl-5\">\r\n\t<div class=\"news-cell\">\r\n\t\t<div>\r\n\t\t\t<p><strong>Get a Sneak Peek of the 2027 Agenda!<\/strong><\/p>\r\n\t\t\t<a href=\".\/agenda\/\">View Agenda<\/a>\r\n\t\t<\/div>\r\n\t<\/div>\r\n<\/div>\r\n<\/div>\r\n<\/div>\r\n<\/div>\r\n<!-- #2 NEWS END -->\r\n\r\n\r\n\r\n\r\n<!-- UPPER START -->\r\n<style>\r\n#featured-component { background-color: var(--light-grey); }\r\n<\/style>\r\n<div class=\"row\" id=\"featured-component\">\r\n<div class=\"container\">\r\n\r\n\r\n<!-- #3 OPENING START -->\r\n<style>\r\n#intro-component .img-wrap img { border-radius: 2px; }\r\n#intro-component .vid-wrap { background-color: rgba(120, 120, 120, 0.1); padding: 24px; border-radius: 2px; justify-content: center; }\r\n#intro-component .vid-wrap iframe { aspect-ratio: 16 \/ 9; width: 100% !important; margin-bottom: 6px !important; }\r\n#intro-component .vid-wrap p { margin-bottom: 5px !important; font-size: 14px; line-height: 24px !important; }\r\n#intro-component .callout { background-color: rgba(120, 120, 120, 0.1); padding: 16px; border-radius: 2px; }\r\n#intro-component .callout p { color: var(--textcolor-b) !important; margin-bottom: 0 !important; }\r\n@media (min-width: 320px) { #intro-component .copy-wrap { padding: 0; } }\r\n@media (min-width: 768px) { .img-wrap img { width: 100%; } }\r\n@media (min-width: 1024px) { #intro-component .copy-wrap { padding: 0 24px 0 0; } }\r\n<\/style>\r\n<div class=\"row\" id=\"intro-component\">\r\n<div class=\"container\">\r\n<div class=\"row\">\r\n<div class=\"col-xxxs-12 col-md-10 col-lg-8 col-xl-8\">\r\n\t<div class=\"copy-wrap\">\r\n\t\t<h2>Preparing for the Next Era of Controlled Substances Regulation, Enforcement, and Compliance<\/h2>\r\n\t\t<p>The controlled substances landscape is entering another period of significant regulatory and enforcement change. Legal, compliance, and regulatory leaders must navigate evolving DEA and DOJ priorities, heightened scrutiny around diversion and suspicious-order monitoring, changing telemedicine requirements, quota and supply pressures, and growing enforcement risk across manufacturers, distributors, pharmacies, healthcare providers, and prescribers.<\/p>\r\n\t\t<p>At the same time, AI-driven compliance tools, digital commerce, emerging substances, and shifting federal and state policy are creating new operational and legal challenges across the market.<\/p>\r\n\t\t<p>Join industry leaders, regulators, legal practitioners, and compliance executives at the 8th Annual Summit on Controlled Substances: Regulation, Litigation, and Enforcement to benchmark compliance strategies, understand where enforcement is heading, and prepare for the next wave of controlled substances risk.<\/p>\r\n\t<\/div>\r\n<\/div>\r\n<\/div>\r\n<\/div>\r\n<\/div>\r\n<!-- #3 OPENING END -->\r\n\r\n\r\n<hr>\r\n\r\n\r\n<!-- #4 SPEAKERS START -->\r\n<style>\r\n#featured-speakers-component .speaker-grid { display: grid; justify-content: left; margin: 25px auto 49px !important; }\r\n#featured-speakers-component .speaker-grid .speaker-card { overflow: hidden; text-align: left; }\r\n#featured-speakers-component .speaker-grid .speaker-card img { width: 100%; aspect-ratio: 1 \/ 1; object-fit: cover; display: block; border-radius: 3px; }\r\n#featured-speakers-component .speaker-grid .speaker-card .speaker-content { padding: 11px 0 4px; }\r\n#featured-speakers-component .speaker-grid .speaker-card .speaker-content h3 { margin: 0 0 3px !important; font-size: 16px; line-height: 24px; font-weight: bold; }\r\n#featured-speakers-component .speaker-grid .speaker-card .position { margin: 0; font-size: 14px; line-height: 20px; font-weight: normal; color: rgba(36, 36, 36, 0.6) }\r\n#featured-speakers-component .speaker-grid .speaker-card .company { margin: 0; font-size: 14px; line-height: 20px; font-weight: 500; color: var(--textcolor-b); }\r\n\/* Mobile *\/\r\n@media (min-width: 320px) {\r\n\t#featured-speakers-component .speaker-grid {\r\n\t\tmargin-left: 0;\r\n\t\tgrid-template-columns: repeat(auto-fit, 120px);\r\n\t\tgap: 12px;\r\n\t\tmax-width: 296px;\r\n\t}\r\n\t#featured-speakers-component .speaker-grid .speaker-card {\r\n\t\twidth: 120px;\r\n\t}\r\n}\r\n@media (min-width: 375px) {\r\n\t#featured-speakers-component .speaker-grid {\r\n\t\tgrid-template-columns: repeat(auto-fit, 120px);\r\n\t\tgap: 12px;\r\n\t\tmax-width: 348px;\r\n\t}\r\n\t#featured-speakers-component .speaker-grid .speaker-card {\r\n\t\twidth: 120px;\r\n\t}\r\n}\r\n@media (min-width: 425px) {\r\n\t#featured-speakers-component .speaker-grid {\r\n\t\tgrid-template-columns: repeat(auto-fit, 168px);\r\n\t\tgap: 24px;\r\n\t\tmax-width: 360px;\r\n\t}\r\n\t#featured-speakers-component .speaker-grid .speaker-card {\r\n\t\twidth: 168px;\r\n\t}\r\n}\r\n\/* Tablet *\/\r\n@media (min-width: 768px) {\r\n\t#featured-speakers-component .speaker-grid {\r\n\t\tmargin: 25px auto !important;\r\n\t\tgrid-template-columns: repeat(auto-fit, 156px);\r\n\t\tgap: 24px;\r\n\t\tmax-width: 696px;\r\n\t}\r\n\t#featured-speakers-component .speaker-grid .speaker-card {\r\n\t\twidth: 156px;\r\n\t}\r\n}\r\n\/* Laptop *\/\r\n@media (min-width: 1024px) {\r\n\t#featured-speakers-component .speaker-grid {\r\n\t\tgrid-template-columns: repeat(auto-fit, 136px);\r\n\t\tgap: 20px;\r\n\t\tmax-width: 928px;\r\n\t}\r\n\t#featured-speakers-component .speaker-grid .speaker-card {\r\n\t\twidth: 136px;\r\n\t}\r\n}\r\n\/* Desktop *\/\r\n@media (min-width: 1280px) {\r\n\t#featured-speakers-component .speaker-grid {\r\n\t\tgrid-template-columns: repeat(auto-fit, 160px);\r\n\t\tgap: 40px;\r\n\t\tmax-width: 1160px;\r\n\t}\r\n\t#featured-speakers-component .speaker-grid .speaker-card {\r\n\t\twidth: 160px;\r\n\t}\r\n}\r\n\/* Large desktop *\/\r\n@media (min-width: 1440px) {\r\n\t#featured-speakers-component .speaker-grid {\r\n\t\tgrid-template-columns: repeat(auto-fit, 160px);\r\n\t\tgap: 40px;\r\n\t\tmax-width: 1160px;\r\n\t}\r\n\t#featured-speakers-component .speaker-grid .speaker-card {\r\n\t\twidth: 160px;\r\n\t}\r\n}\r\n\/* Extra Large desktop *\/\r\n@media (min-width: 1536px) {\r\n\t#featured-speakers-component .speaker-grid {\r\n\t\tgrid-template-columns: repeat(auto-fit, 192px);\r\n\t\tgap: 48px;\r\n\t\tmax-width: 1392px;\r\n\t}\r\n\t#featured-speakers-component .speaker-grid .speaker-card {\r\n\t\twidth: 192px;\r\n\t}\r\n}\r\n<\/style>\r\n<div class=\"row\" id=\"featured-speakers-component\">\r\n<div class=\"container\">\r\n<div class=\"row\">\r\n<div class=\"col-xxxs-12 col-md-12 col-lg-12 col-xl-12\">\r\n\r\n\r\n<h2>Conference <span style=\"white-space:nowrap;\">Co-Chairs<\/span><\/h2>\r\n<div class=\"speaker-grid\">\r\n\t<div class=\"speaker-card\">\r\n\t\t<img decoding=\"async\" src=\"https:\/\/www.americanconference.com\/controlled-substances\/wp-content\/uploads\/sites\/2006\/2025\/07\/jolie-apicella.png\" alt=\"Headshot\" \/>\r\n\t\t<div class=\"speaker-content\">\r\n\t\t\t<h3>Jolie Apicella<\/h3>\r\n\t\t\t<p class=\"position\"><em>Partner<\/em><\/p>\r\n\t\t\t<p class=\"company\">Wiggin and Dana, LLP<\/p>\r\n\t\t\t<p class=\"position\"><em>Former Chief, Civil Health Care Fraud<br>United States Attorney\u2019s Office<\/em><\/p>\r\n\t\t<\/div>\r\n\t<\/div>\r\n\t<div class=\"speaker-card\">\r\n\t\t<img decoding=\"async\" src=\"https:\/\/www.americanconference.com\/controlled-substances\/wp-content\/uploads\/sites\/2006\/2025\/07\/gustav-eyler.png\" alt=\"Headshot\" \/>\r\n\t\t<div class=\"speaker-content\">\r\n\t\t\t<h3>Gus Eyler<\/h3>\r\n\t\t\t<p class=\"position\"><em>Partner<\/em><\/p>\r\n\t\t\t<p class=\"company\">Gibson, Dunn &#038; Crutcher LLP<\/p>\r\n\t\t\t<p class=\"position\"><em>Former Director, Consumer Protection Branch, Civil Division<br>U.S. Department of Justice<\/em><\/p>\r\n\t\t<\/div>\r\n\t<\/div>\r\n\t<div class=\"speaker-card\">\r\n\t\t<img decoding=\"async\" src=\"https:\/\/www.americanconference.com\/controlled-substances\/wp-content\/uploads\/sites\/2006\/2022\/12\/cori-rizman-1.png\" alt=\"Headshot\" \/>\r\n\t\t<div class=\"speaker-content\">\r\n\t\t\t<h3>Cori L. Rizman<\/h3>\r\n\t\t\t<p class=\"position\"><em>Vice President of DEA Compliance<\/em><\/p>\r\n\t\t\t<p class=\"company\">Ascent Pharmaceuticals, Inc.<\/p>\r\n\t\t\t<p class=\"position\"><em>Former Diversion Group Supervisor<br>Drug Enforcement Administration <\/em><\/p>\r\n\t\t<\/div>\r\n\t<\/div>\r\n<\/div>\r\n\r\n\r\n<h2>Hear Directly from Government Officials<\/h2>\r\n<div class=\"speaker-grid\">\r\n\t<div class=\"speaker-card\">\r\n\t\t<img decoding=\"async\" src=\"https:\/\/www.americanconference.com\/controlled-substances\/wp-content\/uploads\/sites\/2006\/2026\/09\/colin-mcdonald.png\" alt=\"Headshot\" \/>\r\n\t\t<div class=\"speaker-content\">\r\n\t\t\t<h3>Colin M. McDonald<\/h3>\r\n\t\t\t<p class=\"position\"><em>Assistant Attorney General, National Fraud Enforcement Division<\/em><\/p>\r\n\t\t\t<p class=\"company\">U.S. Department of Justice<\/p>\r\n\t\t<\/div>\r\n\t<\/div>\r\n\t<div class=\"speaker-card\">\r\n\t\t<img decoding=\"async\" src=\"https:\/\/www.americanconference.com\/controlled-substances\/wp-content\/uploads\/sites\/2006\/2026\/09\/debbie-seguin.png\" alt=\"Headshot\" \/>\r\n\t\t<div class=\"speaker-content\">\r\n\t\t\t<h3>Debbie Seguin<\/h3>\r\n\t\t\t<p class=\"position\"><em>Deputy Director, Office of National Drug Control Policy (ONDCP), Executive Office of the President<\/em><\/p>\r\n\t\t\t<p class=\"company\">The White House<\/p>\r\n\t\t<\/div>\r\n\t<\/div>\r\n        <div class=\"speaker-card\">\r\n\t\t<img decoding=\"async\" src=\"\/wp-content\/uploads\/sites\/2006\/2019\/12\/Dominic.jpg\" alt=\"Headshot\" \/>\r\n\t\t<div class=\"speaker-content\">\r\n\t\t\t<h3>Dominic Chiapperino, Ph.D.<\/h3>\r\n\t\t\t<p class=\"position\"><em>Director, Controlled Substances Staff<\/em><\/p>\r\n\t\t\t<p class=\"company\">Center for Drug Evaluation and Research, U.S. Food and Drug Administration<\/p>\r\n\t\t<\/div>\r\n\t<\/div>\r\n\r\n\t<div class=\"speaker-card\">\r\n\t\t<img decoding=\"async\" src=\"https:\/\/www.americanconference.com\/controlled-substances\/wp-content\/uploads\/sites\/2006\/2022\/12\/matthew-feeley-1.png\" alt=\"Headshot\" \/>\r\n\t\t<div class=\"speaker-content\">\r\n\t\t\t<h3>Matthew Feeley<\/h3>\r\n\t\t\t<p class=\"position\"><em>Chief, USAO SDFL Civil Division<\/em><\/p>\r\n\t\t\t<p class=\"company\">U.S. Department of Justice<\/p>\r\n\t\t<\/div>\r\n\t<\/div>\r\n<\/div>\r\n\r\n\r\n<h2>Featured Speakers<\/h2>\r\n<div class=\"speaker-grid\">\r\n\t<div class=\"speaker-card\">\r\n\t\t<img decoding=\"async\" src=\"https:\/\/www.americanconference.com\/controlled-substances\/wp-content\/uploads\/sites\/2006\/2026\/01\/laura-bray.png\" alt=\"Headshot\" \/>\r\n\t\t<div class=\"speaker-content\">\r\n\t\t\t<h3>Laura Bray<\/h3>\r\n\t\t\t<p class=\"position\"><em>Founder<\/em><\/p>\r\n\t\t\t<p class=\"company\">Angels for Change<\/p>\r\n\t\t<\/div>\r\n\t<\/div>\r\n\t<div class=\"speaker-card\">\r\n\t\t<img decoding=\"async\" src=\"https:\/\/www.americanconference.com\/controlled-substances\/wp-content\/uploads\/sites\/2006\/2022\/03\/joseph-shepherd.png\" alt=\"Headshot\" \/>\r\n\t\t<div class=\"speaker-content\">\r\n\t\t\t<h3>Joseph Shepherd<\/h3>\r\n\t\t\t<p class=\"position\"><em>Global Senior Director, \r\nControlled Substance Leader <\/em><\/p>\r\n\t\t\t<p class=\"company\">Johnson &#038; Johnson Innovative Medicine<\/p>\r\n\t\t<\/div>\r\n\t<\/div>\r\n\t<div class=\"speaker-card\">\r\n\t\t<img decoding=\"async\" src=\"https:\/\/www.americanconference.com\/controlled-substances\/wp-content\/uploads\/sites\/2006\/2026\/09\/joseph-nguyen.png\" alt=\"Headshot\" \/>\r\n\t\t<div class=\"speaker-content\">\r\n\t\t\t<h3>Joseph Nguyen<\/h3>\r\n\t\t\t<p class=\"position\"><em>Director, Controlled Substances &#038; Pharmacy Compliance;<br>Interim Director, Compliance Investigations<br>Office of Institutional Compliance &#038; Audit Services<\/em><\/p>\r\n\t\t\t<p class=\"company\">UT Southwestern Medical Center<\/p>\r\n\t\t<\/div>\r\n\t<\/div>\r\n\t<div class=\"speaker-card\">\r\n\t\t<img decoding=\"async\" src=\"https:\/\/www.americanconference.com\/controlled-substances\/wp-content\/uploads\/sites\/2006\/2026\/09\/rob-park.png\" alt=\"Headshot\" \/>\r\n\t\t<div class=\"speaker-content\">\r\n\t\t\t<h3>Rob Park<\/h3>\r\n\t\t\t<p class=\"position\"><em>Senior Vice President and Associate General Counsel<\/em><\/p>\r\n\t\t\t<p class=\"company\">McKesson<\/p>\r\n\t\t<\/div>\r\n\t<\/div>\r\n\t<div class=\"speaker-card\">\r\n\t\t<img decoding=\"async\" src=\"https:\/\/www.americanconference.com\/controlled-substances\/wp-content\/uploads\/sites\/2006\/2026\/09\/krista-tongring.png\" alt=\"Headshot\" \/>\r\n\t\t<div class=\"speaker-content\">\r\n\t\t\t<h3>Krista Tongring<\/h3>\r\n\t\t\t<p class=\"position\"><em>President, DEA Regulatory Compliance Practice<\/em><\/p>\r\n\t\t\t<p class=\"company\">Guidepost Solutions<\/p>\r\n\t\t\t<p class=\"position\"><em>Former Acting Section Chief, Office of Compliance, Policy Administration Section; Former Senior Attorney, Diversion and Regulatory Litigation Section, Drug Enforcement Administration<\/em><\/p>\r\n\t\t<\/div>\r\n\t<\/div>\r\n\t<div class=\"speaker-card\">\r\n\t\t<img decoding=\"async\" src=\"https:\/\/www.americanconference.com\/controlled-substances\/wp-content\/uploads\/sites\/2006\/2026\/09\/eric-triana.png\" alt=\"Headshot\" \/>\r\n\t\t<div class=\"speaker-content\">\r\n\t\t\t<h3>Eric Triana<\/h3>\r\n\t\t\t<p class=\"position\"><em>Chief Compliance &#038; Legal Officer<\/em><\/p>\r\n\t\t\t<p class=\"company\">Talkiatry<\/p>\r\n\t\t\t<p class=\"position\"><em>Former Deputy Assistant Administrator, Office of Diversion Operations, Diversion Control Division, Drug Enforcement Administration<\/em><\/p>\r\n\t\t<\/div>\r\n\t<\/div>\r\n<\/div>\r\n\r\n\r\n<!--\r\n<br>\r\n<a href=\".\/speakers\/\" class=\"mainlink\">View All Speakers<\/a>\r\n-->\r\n\r\n<\/div>\r\n<\/div>\r\n<\/div>\r\n<\/div>\r\n<!-- #4 SPEAKERS END -->\r\n\r\n\r\n\r\n<hr>\r\n\r\n\r\n\r\n<!-- #6 TOPICS START -->\r\n<style>\r\n#topics-component .flex-grid {\r\n\t--columns: 4;\r\n\t--gap: 36px;\r\n\tdisplay: flex;\r\n\tflex-wrap: wrap;\r\n\tgap: var(--gap);\r\n\tmargin: 17px 0 53px;\r\n}\r\n#topics-component .flex-grid__item {\r\n\tbox-sizing: border-box;\r\n\tflex: 0 0 100%; \/* Mobile: 1 column *\/\r\n\tdisplay: flex;\r\n\talign-items: flex-start;\r\n\tgap: calc(var(--gap) \/ 2);\r\n\tmargin: 0; padding: 0 12px 36px 0; border-bottom: 1px solid var(--bordercolor-b); border-left: 0;\r\n}\r\n#topics-component .flex-grid__item svg { width: 48px; height: 48px; flex: 0 0 48px; }\r\n#topics-component .flex-grid__item svg path { fill: var(--color-a); stroke-width: 0; }\r\n#topics-component .flex-grid__item p { margin-bottom: 0 !important; color: var(--textcolor-b) !important; }\r\n\/* Tablet *\/\r\n@media (min-width: 768px) {\r\n#topics-component .flex-grid__item {\r\n\tflex-basis: calc((100% - (2 * var(--gap))) \/ 3);\r\n\tpadding: 0 0 0 24px; border-bottom: 0; border-left: 1px solid var(--bordercolor-b);\r\n\tflex-direction: column;\r\n\tgap: calc(var(--gap) \/ 3);\r\n\t}\r\n#topics-component .flex-grid__item svg { width: 60px; height: 60px; flex: 0 0 60px; }\r\n}\r\n\/* Desktop *\/\r\n@media (min-width: 1024px) {\r\n#topics-component .flex-grid__item {\r\n\tflex-basis: calc((100% - ((var(--columns) - 1) * var(--gap))) \/ var(--columns));\r\n\t}\r\n}\r\n<\/style>\r\n<div class=\"row\" id=\"topics-component\">\r\n<div class=\"container\">\r\n<div class=\"row\">\r\n<div class=\"col-xxxs-12 col-md-8 col-lg-6 col-xl-6\">\r\n\t<h2>Why You Need to Attend<\/h2>\r\n\t<p>As enforcement priorities evolve and regulatory expectations become increasingly complex, organizations must proactively identify risk, strengthen compliance programs, and prepare for the next generation of regulatory and enforcement challenges.<\/p>\r\n<\/div>\r\n<\/div>\r\n<div class=\"row\">\r\n<div class=\"col-xxxs-12 col-md-12 col-lg-12 col-xl-12\">\r\n<div class=\"flex-grid\">\r\n\r\n\t<div class=\"flex-grid__item\">\r\n<!--GAVEL ICON-->\r\n<svg class=\"cls-1\" id=\"Layer_1\" data-name=\"Layer 1\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" version=\"1.1\" viewBox=\"0 0 72 72\" width=\"72\" height=\"72\"><path d=\"M53.021 49.298h-.043a3 3 0 0 1-2.131-.936l-14.509-15.35a.655.655 0 0 1 .014-.914l2.462-2.462a.654.654 0 0 1 .914-.014L55.08 44.129c.59.562.922 1.318.936 2.131s-.302 1.577-.878 2.153a2.96 2.96 0 0 1-2.11.878ZM37.728 32.573l14.069 14.89c.317.331.742.518 1.195.526.461.022.886-.166 1.21-.49s.497-.756.49-1.21c0-.461-.194-.886-.526-1.195l-14.89-14.069-1.562 1.562Z\"\/><path d=\"M30.643 39.125a1.3 1.3 0 0 1-.922-.382l-7.193-7.193a1.31 1.31 0 0 1 0-1.85l13.889-13.889a1.31 1.31 0 0 1 1.85 0l7.193 7.193a1.303 1.303 0 0 1 0 1.843L31.572 38.736a1.3 1.3 0 0 1-.922.382Zm6.696-22.392L23.45 30.622l7.193 7.193 13.889-13.889zm3.276 39.845H17.568c-.605 0-1.145-.331-1.411-.871s-.209-1.174.151-1.656l2.995-3.982c.295-.396.77-.634 1.26-.634H37.62c.497 0 .965.238 1.26.634l2.995 3.982c.36.482.418 1.116.151 1.656s-.814.871-1.411.871m-20.052-5.832a.28.28 0 0 0-.216.108l-2.995 3.982a.27.27 0 0 0-.029.281.26.26 0 0 0 .245.151h23.04a.27.27 0 0 0 .245-.151.245.245 0 0 0-.029-.281l-2.995-3.982a.27.27 0 0 0-.216-.108H20.556Z\"\/><\/svg>\r\n\t\t<div>\r\n\t\t\t<p>Anticipate the regulatory, enforcement, and policy developments shaping the future of controlled substances oversight<\/p>\r\n\t\t<\/div>\r\n\t<\/div>\r\n\r\n\t<div class=\"flex-grid__item\">\r\n<!--PHONE-->\r\n<svg class=\"cls-1\" data-name=\"Layer 1\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" viewBox=\"0 0 72 72\" width=\"72\" height=\"72\"><path d=\"M45.677 54.648c-.526 0-1.325-.086-2.441-.252-1.123-.173-2.506-.598-4.118-1.26-1.591-.662-3.42-1.663-5.429-2.974-2.009-1.318-4.176-3.139-6.437-5.422-1.793-1.764-3.298-3.485-4.486-5.105-1.181-1.62-2.146-3.139-2.873-4.522-.727-1.39-1.282-2.664-1.642-3.802-.367-1.13-.619-2.131-.749-2.959-.137-.85-.187-1.512-.158-2.023q.034-.64.036-.727v-.086a4.2 4.2 0 0 1 .403-1.274 3.4 3.4 0 0 1 .799-1.094l5.047-5.047c.482-.482 1.051-.727 1.685-.727.475 0 .9.144 1.274.418.31.23.583.526.806.878.007.014.022.029.029.043l4.082 7.74c.302.533.389 1.13.252 1.771a3 3 0 0 1-.828 1.548l-1.836 1.836s0 .014-.007.029c0 .022-.014.036-.014.05.101.446.302.972.605 1.555.295.583.749 1.303 1.361 2.146.612.85 1.498 1.836 2.635 2.945 1.116 1.145 2.117 2.038 2.981 2.664.857.626 1.577 1.087 2.146 1.375.67.346 1.022.461 1.202.497l.353.072s.022-.007.036-.014q.009.002.029-.007l2.138-2.174s.022-.022.036-.029a3 3 0 0 1 2.038-.77q.745 0 1.253.259c.05.014.101.036.144.058l7.358 4.349c.706.432 1.123 1.001 1.26 1.692q-.002.021.007.043c.101.785-.144 1.498-.72 2.074l-5.076 5.033a3.4 3.4 0 0 1-1.073.77 4.4 4.4 0 0 1-1.282.403h-.094l-.166.014a6 6 0 0 1-.562.022ZM18.691 25.654c0 .108-.014.36-.036.742-.022.41.029 1.001.144 1.75.122.763.36 1.692.698 2.765.346 1.066.864 2.275 1.555 3.593.698 1.325 1.627 2.794 2.772 4.356s2.606 3.233 4.356 4.954c2.203 2.225 4.298 3.996 6.228 5.256 1.937 1.267 3.694 2.232 5.213 2.858 1.512.626 2.794 1.022 3.816 1.181q1.566.238 2.246.238c.18 0 .324 0 .439-.014q.14-.011.216-.022c.281-.043.576-.137.871-.281.288-.137.526-.31.698-.497l5.098-5.062c.281-.281.389-.583.346-.95-.043-.209-.166-.511-.655-.806l-7.258-4.284a.7.7 0 0 1-.137-.058c-.101-.065-.31-.137-.691-.137q-.657 0-1.152.432l-2.153 2.196a1.2 1.2 0 0 1-.504.295c-.259.086-.418.115-.59.079l-.475-.094c-.382-.079-.886-.274-1.541-.612-.634-.324-1.39-.806-2.318-1.483-.922-.67-1.973-1.613-3.132-2.801-1.174-1.152-2.11-2.196-2.772-3.103-.655-.907-1.145-1.685-1.469-2.318-.382-.727-.634-1.404-.742-2.002-.007-.043-.014-.079-.014-.122q-.002-.227.094-.497c.072-.216.166-.382.295-.504l1.865-1.865q.359-.355.468-.893a1.18 1.18 0 0 0-.122-.878l-4.075-7.733a1.9 1.9 0 0 0-.475-.511.77.77 0 0 0-.49-.158c-.281 0-.526.108-.756.346l-5.069 5.069a2.2 2.2 0 0 0-.518.72q-.216.443-.281.864Zm10.411 5.911\" \/><\/svg>\r\n\t\t<div>\r\n\t\t\t<p>Prepare for the next phase of telemedicine prescribing under DEA\u2019s Special Registration framework<\/p>\r\n\t\t<\/div>\r\n\t<\/div>\r\n\r\n\t<div class=\"flex-grid__item\">\r\n<!--Cannabis-->\r\n<svg class=\"cls-1\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" viewBox=\"0 0 72 72\" width=\"72\" height=\"72\"><path d=\"M38.657 18.907s.022.014.036.029a.1.1 0 0 1-.036-.029m.223.317.014.108q-.002-.054-.014-.108m-.54 2.93h.007zm-7.128 6.552v.007zm8.172.943v.014zm-10.879 2.714s.007.014.014.014c0 0-.007-.014-.014-.014m2.729.338v.007zm-11.57 1.814v.022zm.144.389.014.014zm29.837 1.253v.007Zm-28.85.187v.014zm1.562 1.98s.007 0 .014.007q-.002.002-.014-.007m25.43 2.002s-.014.014-.022.014c.007 0 .014-.014.022-.014m-28.764 6.84s.036.007.05.014c0 0-.022 0-.05-.014m3.6 1.138h.014zm24.703.338h.007zm-12.614-1.001 1.094.288.05.598a27 27 0 0 0 .806 5.342c.166.648.454 1.469.85 2.441.065.158.115.259.158.324.295-.13.626-.295.958-.49-1.26-2.124-2.059-4.601-2.39-7.394l-.065-.569 1.044-.461 1.67 1.894.338.187q.225.12.396.317c.238.302.742.655.986.713.194.043.374.137.526.274.346.31.468.374.734.403.137.014.281.058.41.122.511.259.965.446 1.354.569a12 12 0 0 0-.619-1.433q-.259-.488-.821-1.202c-.418-.54-.727-.929-.936-1.166l-.374-.425.583-1.022.598.108c.763.166 1.447.23 2.038.202.432-.029.763 0 1.152.029.216.014.454.036.749.043.49.022.72-.058.814-.101a1.1 1.1 0 0 1 .59-.122c.648.022 1.109-.043 1.548-.23a2 2 0 0 1 .454-.122c.547-.058.922-.115 1.188-.324l.115-.086.202-.072.986-.245.209-.158a1.4 1.4 0 0 1 .526-.252 4.6 4.6 0 0 0 1.39-.626 7.3 7.3 0 0 0-1.476-.533h-.022a1.2 1.2 0 0 1-.54-.288c-.115-.108-.475-.144-.742-.18l-.317-.043a1.4 1.4 0 0 1-.482-.18c-.216-.137-.497-.151-.972-.166l-.274-.014c-.166 0-.338-.05-.49-.122-.346-.173-.986-.137-1.411-.108l-.202.014a1.15 1.15 0 0 1-.475-.072c-.05-.014-.238-.014-.562-.058-.569 0-1.181.036-1.822.115l-.54.18-.612-1.159.526-.403 2.858-2.268c.029-.158.144-.446.403-.626a9.6 9.6 0 0 0 1.454-1.354c.043-.223.144-.461.346-.626a7 7 0 0 0 1.001-1.037l.05-.187c.05-.187.151-.367.295-.511.274-.274.518-.576.727-.893q.002-.042.014-.094l.022-.187.122-.209.662-.936.058-.216c.043-.158.101-.295.18-.425l.54-.871.05-.245q.052-.237.158-.41c.288-.49.425-.72.439-.965.014-.173.065-.324.137-.461.108-.202.288-.598.554-1.418.072-.238.13-.418.158-.562-.828.317-1.188.504-1.361.619-.094.058-.245.137-.85.382-.18.072-.36.187-.518.353l-.223.223-.576.043a5.8 5.8 0 0 0-1.037.727l-.166.151-.259.058c-.245.05-.331.094-.331.094a9.5 9.5 0 0 0-1.188.958 1 1 0 0 1-.54.266h-.094a13 13 0 0 0-2.081 1.958.94.94 0 0 1-.605.324c-.086.036-.288.266-.396.389a37 37 0 0 1-.886.958c-.418.446-.85.9-1.217 1.346a63 63 0 0 0-1.375 1.692l-.353.461-1.13-.446.101-.626c.115-.886.18-1.382.187-1.447.029-.497.079-.979.144-1.397.101-.59.18-1.058.072-1.447l-.043-.158.014-.281c.144-1.051.216-2.117.202-3.154l-.202-.324-.022-.288v-2.11l-.115-.302a1.7 1.7 0 0 1-.115-.54l-.101-1.411a.8.8 0 0 0-.072-.31 2.1 2.1 0 0 1-.245-.835c-.029-.619-.122-1.145-.202-1.332a.9.9 0 0 1-.324-.641c-.029-.562-.151-1.21-.252-1.368-.158-.094-.302-.36-.317-.662l-.166-.799c-.05-.266-.122-.346-.122-.346a1.02 1.02 0 0 1-.331-.562c-.216-.922-.504-1.692-.857-2.29a15.6 15.6 0 0 0-.77 2.318c-.05.202-.151.382-.295.533a.64.64 0 0 0-.166.338q-.151.853-.173.95a1.08 1.08 0 0 1-.367.612q-.087.409-.194 1.238a1.34 1.34 0 0 1-.295.677c-.065.079-.079.13-.079.13q-.087.582-.173 1.39a1.4 1.4 0 0 1-.137.482 1.4 1.4 0 0 0-.13.439c-.166 1.274-.374 2.851-.389 4.334 0 .137-.029.288-.079.418-.094.245-.101.338-.101.338-.014.799.05 1.843.202 3.082q.033.272-.065.533c-.05.13-.05.324-.014.554.122.785.259 1.937.403 3.434l.058.554-1.044.468-.396-.432a64 64 0 0 1-.785-.929c-.468-.569-.907-1.102-1.433-1.634-.518-.533-.922-.95-1.195-1.253-.216-.238-.353-.288-.389-.295a1.04 1.04 0 0 1-.59-.389c-.382-.504-1.008-1.109-1.843-1.786-.151-.122-.223-.144-.223-.144-.194-.014-.497-.101-.677-.288a7.2 7.2 0 0 0-1.253-1.015 1 1 0 0 1-.698-.281c-.49-.461-.95-.713-1.145-.727a1.02 1.02 0 0 1-.605-.266 1 1 0 0 0-.439-.252 3.5 3.5 0 0 1-.792-.302 14 14 0 0 0-1.562-.713c.173.655.418 1.296.742 1.951q.097.207.108.425c.007.223.18.576.432.922.158.209.23.468.216.727.014.158.317.562.446.727.166.23.245.403.274.59.036.216.317.648.641.986a1 1 0 0 1 .281.67c.065.137.317.49.792.958.158.158.274.36.31.59 0 .022.007.036.014.058.31.389.634.713.986.986.223.166.36.425.382.713.49.518.994.972 1.498 1.332.187.137.324.324.396.54.007.029.022.058.029.079.936.763 1.843 1.483 2.707 2.16l.446.346-.396 1.073-.583-.014a25 25 0 0 0-2.174-.079c-.05 0-.13.014-.252.058a1.3 1.3 0 0 1-.497.072H24.7c-.475-.036-1.13-.079-1.476.094a1.46 1.46 0 0 1-.662.144 3.5 3.5 0 0 0-.936.079c-.18.094-.245.13-.324.158-.151.065-.31.101-.468.122-.562.065-.749.115-1.037.31a1.2 1.2 0 0 1-.439.187 5 5 0 0 0-1.418.533c.418.266 1.188.583 1.476.655.18.036.353.13.497.259.194.173.475.23.929.317.31.058.497.151.662.288.029.029.245.187 1.195.223.187 0 .374.072.54.187l.094.065c.418.079.886.101 1.382.072h.187l.497.18a6.6 6.6 0 0 0 1.778-.022 1.4 1.4 0 0 1 .547.014c.49.101 1.296-.029 1.944-.122l.835-.122.533.972-.36.432c-.158.166-.432.497-.936 1.21-.648.907-1.102 1.778-1.354 2.57q.733-.247 1.13-.461c.144-.079.302-.137.461-.158.338-.05.49-.158.893-.454a2 2 0 0 1 .461-.252c.346-.13.576-.324.864-.576a5 5 0 0 1 .432-.353c.641-.49 1.224-1.102 1.786-1.858l.317-.432Zm2.866 10.577c-.454 0-1.044-.245-1.49-1.325-.425-1.051-.727-1.908-.914-2.635a28 28 0 0 1-.713-3.902 10 10 0 0 1-.922.806c-.13.094-.245.194-.353.295-.338.295-.727.626-1.332.857-.598.425-.979.677-1.649.785-.403.23-1.008.468-1.8.713-.72.209-1.138-.079-1.325-.274-.554-.547-.331-1.267-.209-1.656.317-1.015.828-2.016 1.548-3.038-.346.014-.691 0-1.001-.058a8.7 8.7 0 0 1-2.282.022l-.259-.065-.216-.094a7.2 7.2 0 0 1-1.742-.122 1.1 1.1 0 0 1-.41-.18l-.05-.036c-.648-.036-1.397-.144-1.894-.526h-.014c-.511-.101-1.087-.209-1.591-.626-.526-.158-2.549-.842-2.758-1.966-.043-.223-.065-.799.598-1.238a6.5 6.5 0 0 1 2.239-.936c.518-.374 1.03-.461 1.627-.526l.115-.05c.108-.058.274-.151.511-.202a5 5 0 0 1 1.318-.115c.648-.338 1.541-.288 2.189-.245h.144c.144-.072.403-.122.648-.122-.338-.274-.684-.547-1.03-.828-.166-.137-.288-.317-.389-.59-.54-.403-1.08-.886-1.606-1.44a1.4 1.4 0 0 1-.374-.691 7 7 0 0 1-1.159-1.224c-.101-.122-.158-.281-.209-.49-.886-.9-1.102-1.411-1.145-1.714-.31-.346-.77-.943-.9-1.57-.324-.432-.72-.979-.749-1.577-.281-.403-.59-.958-.641-1.541a11.8 11.8 0 0 1-.914-2.57c-.158-.727.158-1.13.367-1.31.389-.331.979-.396 1.591-.166.727.274 1.375.569 1.922.864.072.036.209.101.468.173q.52.14.943.497c.626.108 1.26.562 1.735.979h.202l.266.137c.576.36 1.094.756 1.534 1.188.295.05.598.202.922.461.864.698 1.541 1.346 2.009 1.93.338.122.67.36.986.706q.398.442 1.152 1.21c.259.266.497.518.72.785q-.064-.539-.13-.936-.108-.68.065-1.231c-.151-1.274-.216-2.354-.202-3.211 0-.23.065-.49.18-.806.022-1.562.23-3.161.403-4.45.043-.324.137-.626.274-.922.05-.533.115-1.015.173-1.426.043-.281.166-.562.374-.828.086-.662.158-1.13.238-1.44.058-.23.18-.439.367-.612.029-.151.072-.396.13-.749.072-.403.238-.763.497-1.066.252-1.015.612-1.958 1.051-2.743.259-.461.706-.742 1.202-.756.439-.022.936.245 1.21.684.461.742.821 1.649 1.094 2.765.238.259.403.626.497 1.08l.094.482.058.31q.475.574.583 2.002c.223.281.482.871.54 2.246 0 0 .007.065.079.209.13.252.209.554.23.893l.108 1.426.216.605.022.245.058 2.117c.094.151.151.338.158.533.022 1.13-.043 2.29-.202 3.442.166.684.05 1.361-.065 2.016q-.022.128-.043.266a26 26 0 0 1 1.058-1.152c.288-.302.569-.605.821-.886.281-.317.648-.734 1.152-.886a14 14 0 0 1 2.34-2.131l.13-.094.353-.079a12 12 0 0 1 1.26-1.001c.18-.122.41-.216.734-.288.36-.31.814-.612 1.318-.878l.166-.094.338-.029c.259-.223.547-.396.85-.518.31-.122.518-.209.605-.252.36-.23.979-.511 1.879-.85q.667-.249 1.174 0c.216.101.511.331.662.799.043.151.065.281.058.41-.007.295-.108.734-.31 1.361-.23.727-.439 1.253-.626 1.613-.065.569-.324 1.008-.605 1.476l-.209.662-.59.958-.13.49-.727 1.022c-.036.216-.086.367-.18.504a7 7 0 0 1-.893 1.13l-.043.158a1 1 0 0 1-.202.41 8.4 8.4 0 0 1-1.166 1.246l-.022.072q-.086.27-.259.475a11 11 0 0 1-1.613 1.519c-.122.317-.266.518-.461.67l-1.015.806q.43.031.742.137l.058-.029c.583-.036 1.469-.086 2.174.259l.144-.022c.569.022 1.159.036 1.728.396h.173c.475.058 1.058.122 1.526.511.49.115 2.606.677 2.851 1.793.05.216.094.756-.511 1.21-.742.554-1.512.929-2.29 1.13l-.418.317-1.174.302c-.619.41-1.289.49-1.829.547-.821.346-1.577.382-2.167.36-.382.166-.871.238-1.454.23a18 18 0 0 1-.821-.05c-.317-.029-.583-.05-.943-.029a5 5 0 0 1-.641 0c.36.475.634.886.828 1.246.043.079 1.03 1.944.864 2.808-.137.706-.691 1.102-1.39.979-.641-.115-1.375-.389-2.254-.835-.605-.05-1.008-.346-1.418-.706-.691-.202-1.411-.806-1.721-1.195l-.259-.13c.403 1.67 1.022 3.197 1.843 4.529.266.432.252.799.194 1.037s-.223.576-.677.85c-.353.209-.9.511-1.469.734a1.5 1.5 0 0 1-.497.094\" \/><\/svg>\r\n\t\t<div>\r\n\t\t\t<p>Navigate evolving risks associated with marijuana rescheduling, hemp-derived cannabinoids, psychedelics, kratom, and other emerging substances<\/p>\r\n\t\t<\/div>\r\n\t<\/div>\r\n\r\n\t<div class=\"flex-grid__item\">\r\n<!--RX ICON-->\r\n<svg class=\"cls-1\" id=\"Layer_1\" data-name=\"Layer 1\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" version=\"1.1\" viewBox=\"0 0 72 72\" width=\"72\" height=\"72\"><path d=\"M50.926 58.853H21.074a2.54 2.54 0 0 1-2.534-2.534V18.922a2.54 2.54 0 0 1 2.534-2.534h29.844a2.54 2.54 0 0 1 2.534 2.534v37.404a2.54 2.54 0 0 1-2.534 2.534ZM21.074 17.69c-.677 0-1.224.547-1.224 1.224v37.404c0 .677.547 1.224 1.224 1.224h29.844c.677 0 1.224-.547 1.224-1.224V18.922c0-.677-.547-1.224-1.224-1.224H21.074Z\"\/><path d=\"M28.296 33.271a.657.657 0 0 1-.655-.655v-6.062a2.427 2.427 0 0 1 2.426-2.426h2.621a2.427 2.427 0 0 1 0 4.852h-.814l3.11 3.11c.252.252.252.67 0 .922s-.67.252-.922 0l-4.226-4.226a.652.652 0 0 1 .461-1.116h2.39c.619 0 1.123-.504 1.123-1.116s-.504-1.123-1.123-1.123h-2.621c-.619 0-1.123.504-1.123 1.123v6.062c0 .36-.295.655-.655.655Zm15.408 3.931a.65.65 0 0 1-.461-.194l-6.905-6.905a.655.655 0 0 1 0-.922.657.657 0 0 1 .922 0l6.905 6.905a.656.656 0 0 1-.461 1.116\"\/><path d=\"M36.799 37.202a.656.656 0 0 1-.461-1.116l6.905-6.905c.252-.252.67-.252.922 0s.252.67 0 .922l-6.905 6.905a.65.65 0 0 1-.461.194m-4.55 4.112h-7.963c-.36 0-.655-.295-.655-.655s.295-.655.655-.655h7.963c.36 0 .655.295.655.655s-.295.655-.655.655m15.465 5.176H24.278c-.36 0-.655-.295-.655-.655s.295-.655.655-.655h23.436c.36 0 .655.295.655.655s-.295.655-.655.655m0 5.17H24.278c-.36 0-.655-.295-.655-.655s.295-.655.655-.655h23.436c.36 0 .655.295.655.655s-.295.655-.655.655m-1.058-33.97H25.344a.657.657 0 0 1-.655-.655v-.187a3.71 3.71 0 0 1 3.708-3.708h15.206a3.71 3.71 0 0 1 3.708 3.708v.187c0 .36-.295.655-.655.655m-20.614-1.303h19.915a2.405 2.405 0 0 0-2.354-1.937H28.397a2.4 2.4 0 0 0-2.354 1.937\"\/><\/svg>\r\n\t\t<div>\r\n\t\t\t<p>Strengthen diversion prevention, prescription validity, and monitoring programs in an era of heightened enforcement<\/p>\r\n\t\t<\/div>\r\n\t<\/div>\r\n\r\n\t<div class=\"flex-grid__item\">\r\n<!--BRAIN-->\r\n<svg class=\"cls-1\" id=\"Layer_1\" data-name=\"Layer 1\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" version=\"1.1\" viewBox=\"0 0 72 72\" width=\"72\" height=\"72\"><path class=\"cls-1\" d=\"M42.847 27.482a.653.653 0 0 1-.598-.907 2.91 2.91 0 1 0-5.588-1.13c0 .36-.295.655-.655.655s-.655-.295-.655-.655a4.225 4.225 0 0 1 4.219-4.219 4.225 4.225 0 0 1 3.888 5.861.65.65 0 0 1-.605.396Zm-3.283 23.292a4.225 4.225 0 0 1-4.219-4.219c0-.36.295-.655.655-.655s.655.295.655.655a2.91 2.91 0 0 0 5.818 0c0-.396-.079-.778-.23-1.13a.65.65 0 0 1 .346-.857.653.653 0 0 1 .857.346 4.225 4.225 0 0 1-3.888 5.861Z\"\/><path class=\"cls-1\" d=\"M43.258 47.65a.647.647 0 0 1-.648-.605.65.65 0 0 1 .605-.698c3.629-.266 6.372-3.434 6.106-7.063a6.5 6.5 0 0 0-.958-2.974.654.654 0 1 1 1.116-.684 8 8 0 0 1 1.145 3.564c.317 4.349-2.966 8.143-7.315 8.46zm3.974-16.164a.652.652 0 0 1-.583-.936 3.65 3.65 0 0 0 .158-2.794 3.6 3.6 0 0 0-1.865-2.081 3.5 3.5 0 0 0-1.692-.36.65.65 0 0 1-.67-.634.65.65 0 0 1 .634-.67 5 5 0 0 1 2.297.49 4.9 4.9 0 0 1 2.527 2.83 4.94 4.94 0 0 1-.209 3.787.65.65 0 0 1-.59.367Z\"\/><path class=\"cls-1\" d=\"M47.743 38.261a.656.656 0 0 1-.461-1.116 5.285 5.285 0 0 0 0-7.466.655.655 0 0 1 0-.922.657.657 0 0 1 .922 0 6.593 6.593 0 0 1 0 9.317.65.65 0 0 1-.461.194ZM36 47.268a.657.657 0 0 1-.655-.655V25.43c0-.36.295-.655.655-.655s.655.295.655.655v21.182c0 .36-.295.655-.655.655m4.882-14.997a.655.655 0 0 1-.648-.59c-.187-1.836-1.138-2.095-1.174-2.102a.665.665 0 0 1-.49-.778.65.65 0 0 1 .756-.504c.079.014 1.915.403 2.21 3.254a.66.66 0 0 1-.583.72h-.065Zm3.708 9.735h-.122a.655.655 0 0 1-.583-.72.647.647 0 0 1 .691-.583c.05 0 .554-.036.95-.986.137-.331.526-.49.857-.353s.49.526.353.857c-.598 1.418-1.577 1.786-2.146 1.786m-.944-5.243a.65.65 0 0 1-.569-.331.65.65 0 0 1 .245-.893c1.361-.778.871-1.908.763-2.124a.655.655 0 0 1 .281-.878.65.65 0 0 1 .878.274c.439.835.749 2.714-1.274 3.874a.65.65 0 0 1-.324.086Zm-2.851 5.983a.6.6 0 0 1-.194-.029c-.9-.274-2.448-1.39-1.836-3.636a.655.655 0 0 1 .799-.461.656.656 0 0 1 .461.799c-.425 1.57.814 2.002.958 2.045a.65.65 0 0 1 .432.814.65.65 0 0 1-.626.461Z\"\/><path class=\"cls-1\" d=\"M32.436 50.774a4.225 4.225 0 0 1-3.888-5.861.653.653 0 1 1 1.202.511 2.91 2.91 0 1 0 5.588 1.13c0-.36.295-.655.655-.655s.655.295.655.655a4.225 4.225 0 0 1-4.219 4.219Zm-3.283-23.292a.67.67 0 0 1-.605-.396 4.225 4.225 0 0 1 3.888-5.861 4.225 4.225 0 0 1 4.219 4.219c0 .36-.295.655-.655.655s-.655-.295-.655-.655a2.91 2.91 0 0 0-5.818 0c0 .396.079.778.23 1.13a.65.65 0 0 1-.598.907Z\"\/><path class=\"cls-1\" d=\"M23.083 36.691a.65.65 0 0 1-.554-.31 8 8 0 0 1-1.145-3.564c-.317-4.349 2.966-8.143 7.315-8.46a.654.654 0 0 1 .094 1.303c-3.629.266-6.372 3.434-6.106 7.063a6.5 6.5 0 0 0 .958 2.974.65.65 0 0 1-.554.994Zm5.566 11.304a4.96 4.96 0 0 1-2.153-.49c-2.462-1.188-3.506-4.154-2.318-6.617a.652.652 0 1 1 1.174.569 3.657 3.657 0 0 0 1.706 4.874 3.5 3.5 0 0 0 1.692.36.65.65 0 0 1 .67.634.66.66 0 0 1-.634.677h-.144Z\"\/><path class=\"cls-1\" d=\"M24.257 43.438a.65.65 0 0 1-.461-.194 6.593 6.593 0 0 1 0-9.317c.252-.252.67-.252.922 0s.252.67 0 .922a5.285 5.285 0 0 0 0 7.466.656.656 0 0 1-.461 1.116ZM36 47.225a.657.657 0 0 1-.655-.655V25.387c0-.36.295-.655.655-.655s.655.295.655.655v21.182c0 .36-.295.655-.655.655m-3.859-15.918a.65.65 0 0 1-.576-.346 3.28 3.28 0 0 1-.245-2.498 3.25 3.25 0 0 1 1.591-1.937.654.654 0 0 1 .619 1.152c-.468.245-.806.662-.958 1.166s-.101 1.037.144 1.505a.655.655 0 0 1-.576.965Zm-.447 7.934a.65.65 0 0 1-.576-.346c-.446-.835-.749-2.714 1.274-3.874.317-.18.713-.072.893.245s.072.713-.245.893c-1.361.778-.871 1.908-.763 2.124a.654.654 0 0 1-.583.95Zm-3.628-4.054q-.086 0-.173-.022a.655.655 0 0 1-.461-.799c.425-1.57-.814-2.002-.958-2.045a.65.65 0 0 1-.432-.814.65.65 0 0 1 .814-.432c.9.274 2.448 1.39 1.836 3.636a.66.66 0 0 1-.634.482Zm2.404 7.676a.66.66 0 0 1-.634-.49c-.086-.324-.756-.59-1.102-.662a.645.645 0 0 1-.504-.77.655.655 0 0 1 .77-.511c.18.036 1.786.396 2.102 1.62a.655.655 0 0 1-.634.821ZM36 17.338a.657.657 0 0 1-.655-.655v-4.054c0-.36.295-.655.655-.655s.655.295.655.655v4.054c0 .36-.295.655-.655.655m-9.655 2.592a.66.66 0 0 1-.569-.324L23.753 16.1c-.18-.31-.072-.713.238-.893s.713-.072.893.238l2.023 3.506c.18.31.072.713-.238.893a.65.65 0 0 1-.324.086M19.274 27a.65.65 0 0 1-.324-.086l-3.506-2.023a.655.655 0 0 1-.238-.893.657.657 0 0 1 .893-.238l3.506 2.023A.65.65 0 0 1 19.274 27m-2.584 9.655h-4.054c-.36 0-.655-.295-.655-.655s.295-.655.655-.655h4.054c.36 0 .655.295.655.655s-.295.655-.655.655m-.922 11.679a.66.66 0 0 1-.569-.324.657.657 0 0 1 .238-.893l3.506-2.023c.31-.18.713-.072.893.238s.072.713-.238.893l-3.506 2.023a.65.65 0 0 1-.324.086m8.546 8.553a.65.65 0 0 1-.324-.086.655.655 0 0 1-.238-.893l2.023-3.506c.18-.31.583-.418.893-.238s.418.583.238.893l-2.023 3.506a.65.65 0 0 1-.569.324M36 60.019a.657.657 0 0 1-.655-.655V55.31c0-.36.295-.655.655-.655s.655.295.655.655v4.054c0 .36-.295.655-.655.655m11.686-3.132a.66.66 0 0 1-.569-.324l-2.023-3.506c-.18-.31-.072-.713.238-.893s.713-.072.893.238l2.023 3.506c.18.31.072.713-.238.893a.65.65 0 0 1-.324.086m8.546-8.553a.65.65 0 0 1-.324-.086l-3.506-2.023a.655.655 0 0 1-.238-.893.657.657 0 0 1 .893-.238l3.506 2.023a.65.65 0 0 1-.331 1.217m3.132-11.679H55.31c-.36 0-.655-.295-.655-.655s.295-.655.655-.655h4.054c.36 0 .655.295.655.655s-.295.655-.655.655M52.726 27a.66.66 0 0 1-.569-.324.657.657 0 0 1 .238-.893l3.506-2.023c.31-.18.713-.072.893.238s.072.713-.238.893l-3.506 2.023a.65.65 0 0 1-.324.086m-7.071-7.07a.65.65 0 0 1-.324-.086.655.655 0 0 1-.238-.893l2.023-3.506c.18-.31.583-.418.893-.238s.418.583.238.893l-2.023 3.506a.65.65 0 0 1-.569.324\"\/><\/svg>\r\n\t\t<div>\r\n\t\t\t<p>Leverage AI, data analytics, ARCOS intelligence, and advanced monitoring tools to identify and mitigate compliance&nbsp;risk<\/p>\r\n\t\t<\/div>\r\n\t<\/div>\r\n\r\n\t<div class=\"flex-grid__item\">\r\n<!--LOOKING GLASS CONNECTION ICON-->\r\n<svg class=\"cls-1\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" viewBox=\"0 0 72 72\" width=\"72\" height=\"72\"><path d=\"M57.78,22.64c.04-.75-.22-1.48-.73-2.03-.51-.55-1.2-.88-1.96-.91-.76-.04-1.48.22-2.04.73-.55.51-.88,1.2-.91,1.96-.03.59.13,1.17.45,1.66l-4.35,4.09c-1.72-5.77-7.06-9.99-13.38-9.99-7.7,0-13.97,6.26-13.97,13.97,0,.8.08,1.58.21,2.34l-2.58,2.66c-.4-.25-.86-.4-1.34-.42-.75-.04-1.48.22-2.03.73s-.88,1.2-.91,1.96c-.04.75.22,1.48.73,2.03.51.55,1.2.88,1.96.91h.13,0c1.5,0,2.76-1.18,2.82-2.69.03-.57-.12-1.13-.42-1.61l1.99-2.06c1.68,5.83,7.05,10.11,13.41,10.11,2.89,0,5.58-.88,7.81-2.4l9.38,9.38c.5.5,1.17.78,1.87.78h0c.71,0,1.37-.27,1.89-.78,1.03-1.04,1.03-2.71,0-3.74l-9.35-9.35s-.03-.01-.04-.03c1.52-2.23,2.41-4.93,2.41-7.83,0-.86-.09-1.7-.24-2.52l4.96-4.66c.39.23.82.37,1.29.39h.13c1.5,0,2.76-1.18,2.82-2.69ZM16.98,41.02c-.4-.01-.78-.19-1.05-.49-.27-.3-.41-.69-.4-1.09s.19-.78.49-1.05c.28-.26.64-.4,1.02-.4h.07c.4.01.78.19,1.05.49.27.3.41.69.4,1.09-.04.84-.76,1.49-1.58,1.45ZM22.2,32.12c0-6.98,5.67-12.66,12.66-12.66,5.96,0,10.96,4.15,12.29,9.7l-4.25,4c-.38-.22-.81-.36-1.27-.38-.75-.04-1.48.22-2.03.73-.06.06-.11.13-.17.19l-8.19-5c.1-.27.17-.55.18-.84.07-1.56-1.14-2.88-2.69-2.95-1.54-.06-2.88,1.14-2.95,2.7-.03.59.13,1.14.42,1.61l-3.94,4.06c-.03-.38-.06-.76-.06-1.15ZM40.48,34.46c.28-.26.64-.4,1.02-.4h.07c.84.04,1.48.75,1.45,1.58-.04.84-.76,1.49-1.58,1.45-.4-.01-.78-.19-1.05-.49-.27-.3-.42-.69-.4-1.09.01-.4.19-.78.49-1.05ZM27.08,27.66c.04-.81.71-1.45,1.52-1.45h.06c.84.04,1.48.75,1.45,1.58s-.76,1.48-1.58,1.45c-.84-.04-1.48-.75-1.45-1.58ZM54.88,50.24c.53.52.53,1.37-.01,1.91-.5.5-1.39.5-1.89,0l-9.25-9.25c.7-.57,1.34-1.21,1.91-1.91l9.25,9.25ZM47.51,32.12c0,6.98-5.68,12.66-12.66,12.66-6.03,0-11.08-4.25-12.35-9.9l4.61-4.75c.4.25.85.41,1.35.43h.13c.74,0,1.41-.29,1.92-.76l8.27,5.05c-.06.2-.09.41-.1.62-.04.75.22,1.48.73,2.03.51.55,1.2.88,1.96.91h.13c1.5.01,2.76-1.17,2.82-2.69.03-.62-.16-1.19-.47-1.68l3.57-3.36c.05.47.09.94.09,1.43ZM54.89,24.02c-.4-.01-.78-.19-1.05-.49-.27-.3-.41-.69-.4-1.09s.19-.78.49-1.05c.28-.26.64-.4,1.02-.4h.07c.4.01.78.19,1.05.49s.41.69.4,1.09c-.04.84-.75,1.49-1.58,1.45Z\"\/><\/svg>\r\n\t\t<div>\r\n\t\t\t<p>Manage healthcare fraud, dispensing liability, supply chain, and quota-related challenges through practical compliance strategies<\/p>\r\n\t\t<\/div>\r\n\t<\/div>\r\n\r\n\t<div class=\"flex-grid__item\">\r\n<!--SCALES-->\r\n<svg class=\"cls-1\" id=\"Layer_1\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" version=\"1.1\" viewBox=\"0 0 72 72\" width=\"72\" height=\"72\"><path class=\"st0\" d=\"M21.218 47.203c-4.716 0-8.273-3.312-8.273-7.711 0-.396.324-.72.72-.72h15.098c.396 0 .72.324.72.72 0 4.399-3.557 7.711-8.273 7.711Zm-6.79-6.991c.353 3.254 3.103 5.551 6.79 5.551s6.437-2.297 6.79-5.551H14.422Z\"\/><path class=\"st0\" d=\"M27.036 40.212a.72.72 0 0 1-.648-.403l-5.17-10.634-5.17 10.634a.72.72 0 0 1-.965.331.72.72 0 0 1-.331-.965l5.818-11.966c.238-.497 1.051-.497 1.296 0l5.818 11.966a.73.73 0 0 1-.331.965.7.7 0 0 1-.317.072M44.87 52.43a.72.72 0 0 1-.72-.72v-1.001a1.8 1.8 0 0 0-1.8-1.8H29.664a1.8 1.8 0 0 0-1.8 1.8v1.001c0 .396-.324.72-.72.72s-.72-.324-.72-.72v-1.001a3.244 3.244 0 0 1 3.24-3.24H42.35a3.244 3.244 0 0 1 3.24 3.24v1.001c0 .396-.324.72-.72.72\"\/><path class=\"st0\" d=\"M47.83 55.958a.72.72 0 0 1-.72-.72v-.756c0-1.13-.914-2.045-2.045-2.045H26.928c-1.13 0-2.045.914-2.045 2.045v.756c0 .396-.324.72-.72.72s-.72-.324-.72-.72v-.756a3.49 3.49 0 0 1 3.485-3.485h18.137a3.49 3.49 0 0 1 3.485 3.485v.756c0 .396-.324.72-.72.72M36 48.902a.72.72 0 0 1-.72-.72V20.578c0-.396.324-.72.72-.72s.72.324.72.72v27.605c0 .396-.324.72-.72.72\"\/><path class=\"st0\" d=\"M21.161 28.246c-1.08 0-2.254-.331-3.542-1.166a.713.713 0 0 1-.209-.994.714.714 0 0 1 .994-.209c3.139 2.038 5.285.36 7.762-1.584 2.743-2.146 5.846-4.586 10.296-.965.31.252.353.706.108 1.015a.727.727 0 0 1-1.015.108c-3.557-2.894-5.846-1.094-8.496.986-1.728 1.354-3.607 2.83-5.89 2.83Zm30.074 27.712h-30.47c-.396 0-.72-.324-.72-.72s.324-.72.72-.72h30.47c.396 0 .72.324.72.72s-.324.72-.72.72m-.453-8.755c-4.716 0-8.273-3.312-8.273-7.711 0-.396.324-.72.72-.72h15.098c.396 0 .72.324.72.72 0 4.399-3.557 7.711-8.273 7.711Zm-6.79-6.991c.353 3.254 3.103 5.551 6.79 5.551s6.437-2.297 6.79-5.551H43.985Z\"\/><path class=\"st0\" d=\"M56.599 40.212a.72.72 0 0 1-.648-.403l-5.17-10.634-5.17 10.634c-.173.36-.605.504-.965.331s-.504-.605-.331-.965l5.818-11.966c.238-.497 1.051-.497 1.296 0l5.818 11.966a.73.73 0 0 1-.331.965.7.7 0 0 1-.317.072\"\/><path class=\"st0\" d=\"M50.839 28.246c-2.282 0-4.162-1.476-5.89-2.83-2.657-2.081-4.946-3.874-8.496-.986a.721.721 0 1 1-.907-1.123c4.442-3.614 7.553-1.181 10.296.965 2.477 1.944 4.622 3.622 7.762 1.584a.72.72 0 0 1 .994.209.72.72 0 0 1-.209.994c-1.289.835-2.462 1.166-3.542 1.166ZM36 21.298c-1.447 0-2.628-1.181-2.628-2.628s1.181-2.628 2.628-2.628 2.628 1.181 2.628 2.628-1.181 2.628-2.628 2.628m0-3.816c-.655 0-1.188.533-1.188 1.188s.533 1.188 1.188 1.188 1.188-.533 1.188-1.188-.533-1.188-1.188-1.188\"\/><\/svg>\r\n\t\t<div>\r\n\t\t\t<p>Stay ahead of evolving federal and state enforcement trends to reduce legal, regulatory, and operational exposure<\/p>\r\n\t\t<\/div>\r\n\t<\/div>\r\n\r\n<\/div>\r\n\r\n<a href=\".\/agenda\/\" class=\"mainlink\">View Agenda<\/a>\r\n\r\n<\/div>\r\n<\/div>\r\n<\/div>\r\n<\/div>\r\n<!-- #6 TOPICS END -->\r\n\r\n\r\n\r\n\r\n<!-- UPPER END -->\r\n<\/div>\r\n<\/div>\r\n\r\n\r\n\r\n<!-- #8 ATTENDEES START -->\r\n<style>\r\n#attend-component { background-color: var(--dark-grey); }\r\n#attend-component h2, #attend-component h5, #attend-component p, #attend-component li, #attend-component a { color: var(--textcolor-a) !important; }\r\n#attend-component hr { border-top: 1px solid var(--bordercolor-a); }\r\n#attend-component ul { margin: 0 0 24px 18px !important; padding-inline-start: 0 !important; }\r\n#attend-component ul li { margin-bottom: 6px; }\r\n#attend-component ul.org-list { list-style: none; }\r\n#attend-component .flex-grid {\r\n\t--columns: 3;\r\n\t--gap: 36px;\r\n\tdisplay: flex;\r\n\tflex-wrap: wrap;\r\n\tgap: var(--gap);\r\n\tmargin: 17px 0 29px;\r\n}\r\n#attend-component .flex-grid__item {\r\n\tbox-sizing: border-box;\r\n\tflex: 0 0 100%; \/* Mobile: 1 column *\/\r\n\tdisplay: flex;\r\n\talign-items: flex-start;\r\n\tgap: calc(var(--gap) \/ 2);\r\n\tmargin: 0; padding: 0 12px 36px 0; border-bottom: 1px solid var(--bordercolor-a); border-left: 0;\r\n}\r\n#attend-component .flex-grid__item:last-of-type {\r\n\tborder-bottom: 0;\r\n}\r\n#attend-component .flex-grid__item svg { width: 48px; height: 48px; flex: 0 0 48px; }\r\n#attend-component .flex-grid__item svg path { fill: var(--color-b); stroke-width: 0; }\r\n#attend-component .flex-grid__item p { margin-bottom: 0 !important; color: var(--textcolor-c) !important; }\r\n\/* Mobile *\/\r\n@media (min-width: 320px) {\r\n\t#attend-component .list-wrap { margin: 24px 0 0 !important; }\r\n\t#attend-component ul.org-list { margin: 24px 0 48px !important; column-count: 2; column-gap: 2rem; }\r\n}\r\n\/* Tablet *\/\r\n@media (min-width: 768px) {\r\n\t#attend-component .list-wrap { margin: 16px 0 0 !important; padding-right: 48px; }\r\n\t#attend-component ul.org-list { margin: 12px 0 48px !important; column-count: 4; column-gap: 3rem; }\r\n\t#attend-component .flex-grid__item {\r\n\t\tflex-basis: calc((100% - (2 * var(--gap))) \/ 3);\r\n\t\tpadding: 0 0 0 24px; border-bottom: 0; border-left: 1px solid var(--bordercolor-a);\r\n\t\tflex-direction: column;\r\n\t\tgap: calc(var(--gap) \/ 3);\r\n\t}\r\n\t#attend-component .flex-grid__item svg { width: 60px; height: 60px; flex: 0 0 60px; }\r\n}\r\n\/* Desktop *\/\r\n@media (min-width: 1024px) {\r\n\t#attend-component .flex-grid__item {\r\n\t\tflex-basis: calc((100% - ((var(--columns) - 1) * var(--gap))) \/ var(--columns));\r\n\t}\r\n}\r\n<\/style>\r\n<div class=\"row\" id=\"attend-component\">\r\n<div class=\"container\">\r\n<div class=\"row\">\r\n<div class=\"col-xxxs-12 col-md-8 col-lg-6 col-xl-6\">\r\n      <h2>Our Audience at a Glance<\/h2>\r\n<\/div>\r\n<\/div>\r\n<div class=\"row\">\r\n<div class=\"col-xxxs-12 col-md-12 col-lg-12 col-xl-12\">\r\n<div class=\"flex-grid\">\r\n\r\n<style>\r\n:root {\r\n    --percentage: 75; \/* 0-100 *\/\r\n    --color: #2563eb;\r\n    --size: 160px;\r\n    --track-color: #242424;\r\n    --thickness: 24px;\r\n}\r\n\r\n#attend-component .percentage-chart {\r\n    width: var(--size);\r\n    aspect-ratio: 1;\r\n    border-radius: 50%;\r\n    position: relative;\r\n    display: grid;\r\n    place-items: center;\r\n    background:\r\n        conic-gradient(\r\n            var(--color) calc(var(--percentage) * 1%),\r\n            var(--track-color) 0\r\n        );\r\n}\r\n\r\n#attend-component .percentage-chart::before {\r\n    content: \"\";\r\n    position: absolute;\r\n    inset: var(--thickness);\r\n    background: #121212;\r\n    border-radius: 50%;\r\n}\r\n\r\n#attend-component .percentage-value {\r\n    position: relative;\r\n    z-index: 1;\r\n    font-family: sans-serif;\r\n    font-size: clamp(1.5rem, 4vw, 3rem);\r\n    font-weight: 700;\r\n    color: var(--color);\r\n}\r\n<\/style>\r\n\r\n\t<div class=\"flex-grid__item\">\r\n\r\n<div class=\"percentage-chart\" style=\"--percentage: 48; --color: #a55beb;\">\r\n    <div class=\"percentage-value\">48%<\/div>\r\n<\/div>\r\n\r\n          <h4 style=\"color:#a55beb !important;\">Pharmaceutical\/ Biotechnology Research Organizations<\/h4>\r\n \t  <p>General Counsel<\/p>\r\n \t  <p>Officers, Executives, Vice Presidents, Directors, and Senior Managers of:<\/p>\r\n\t  <ul>\r\n\t\t<li>Controlled Substances<\/li>\r\n\t\t<li>Pharmacy Compliance<\/li>\r\n\t\t<li>Diversion Control<\/li>\r\n\t\t<li>DEA Compliance<\/li>\r\n\t\t<li>Regulatory &#038; Compliance Operations<\/li>\r\n\t\t<li>Quality Compliance<\/li>\r\n\t\t<li>Ethics<\/li>\r\n\t\t<li>Abuse &#038; Risk Assessment<\/li>\r\n\t  <\/ul>\r\n\r\n\t<\/div>\r\n\r\n\t<div class=\"flex-grid__item\">\r\n\r\n<div class=\"percentage-chart\" style=\"--percentage: 14; --color: #e6eb5b;\">\r\n    <div class=\"percentage-value\">14%<\/div>\r\n<\/div>\r\n\r\n          <h4 style=\"color:#e6eb5b !important;\">Healthcare<\/h4>\r\n \t  <p>General Counsel<\/p>\r\n \t  <p>Officers, Executives, Vice Presidents, Directors, and Senior Managers of:<\/p>\r\n\t  <ul>\r\n\t\t<li>Pharmacy<\/li>\r\n\t\t<li>Diversion Control<\/li>\r\n\t\t<li>Operations<\/li>\r\n\t\t<li>Procurement<\/li>\r\n\t\t<li>Distribution<\/li>\r\n\t\t<li>Regulatory Affairs &#038; Compliance<\/li>\r\n\t\t<li>Quality Management<\/li>\r\n\t\t<li>DEA Compliance<\/li>\r\n\t  <\/ul>\r\n\r\n\t<\/div>\r\n\r\n\t<div class=\"flex-grid__item\">\r\n\r\n<div class=\"percentage-chart\" style=\"--percentage: 10; --color: #5badeb;\">\r\n    <div class=\"percentage-value\">10%<\/div>\r\n<\/div>\r\n\r\n          <h4 style=\"color:#5badeb !important;\">Retail Manufacturers and Pharmacies<\/h4>\r\n \t  <p>Pharmacists<\/p>\r\n \t  <p>Officers, Executives, Vice Presidents, Directors, and Senior Managers of:<\/p>\r\n\t  <ul>\r\n\t\t<li>Controlled Substances<\/li>\r\n\t\t<li>Operations<\/li>\r\n\t\t<li>Regulatory Affairs &#038; Compliance<\/li>\r\n\t\t<li>Investigations<\/li>\r\n\t\t<li>Professional Practice<\/li>\r\n\t\t<li>DEA Compliance<\/li>\r\n\t  <\/ul>\r\n\r\n\t<\/div>\r\n\r\n\t<div class=\"flex-grid__item\">\r\n\r\n<div class=\"percentage-chart\" style=\"--percentage: 11; --color: #eb5f5b;\">\r\n    <div class=\"percentage-value\">11%<\/div>\r\n<\/div>\r\n\r\n          <h4 style=\"color:#eb5f5b !important;\">Other Industries including:<\/h4>\r\n\t  <ul>\r\n\t\t<li>Federal &#038; State Level Government Officials<\/li>\r\n\t\t<li>Environmental Services<\/li>\r\n\t\t<li>Logistics Distribution<\/li>\r\n\t  <\/ul>\r\n\r\n\t<\/div>\r\n\r\n\t<div class=\"flex-grid__item\">\r\n\r\n<div class=\"percentage-chart\" style=\"--percentage: 17; --color: #eb8a5b;\">\r\n    <div class=\"percentage-value\">17%<\/div>\r\n<\/div>\r\n\r\n          <h4 style=\"color:#eb8a5b !important;\">Outside Counsel\/Consultants<\/h4>\r\n\r\n\t<\/div>\r\n\r\n<\/div>\r\n<\/div>\r\n<\/div>\r\n\r\n<\/div>\r\n<\/div>\r\n<!-- #8 ATTENDEES END -->\r\n\r\n\r\n\r\n\r\n<!-- FOLD START -->\r\n<style>\r\n#fold-component { background-color: var(--dark-grey); }\r\n:root {\r\n\t--fold-component-margin: 48px;\r\n\t--fold-component-text-color: #F5F5F5;\r\n}\r\n<\/style>\r\n<div class=\"row\" id=\"fold-component\">\r\n<div class=\"container\">\r\n\r\n\r\n\r\n<!-- #14 ARTICLE START -->\r\n<style>\r\n#article-component { margin-bottom: var(--fold-component-margin); }\r\n#article-component .content-wrap { display: flex; background-color: var(--light-grey); border-radius: 2px; overflow: hidden; align-items: center; justify-content: left; }\r\n#article-component .content-wrap .copy-wrap { text-align: center; }\r\n\/* Mobile *\/\r\n@media (min-width: 320px) {\r\n\t#article-component .content-wrap { flex-direction: column-reverse; }\r\n\t#article-component .content-wrap img { width: 100%; }\r\n\t#article-component .content-wrap .copy-wrap { padding: 36px; }\r\n}\r\n\/* Tablet *\/\r\n@media (min-width: 768px) {\r\n\t#article-component .content-wrap .copy-wrap { padding: 48px; }\r\n}\r\n\/* Laptop *\/\r\n@media (min-width: 1024px) {\r\n\t#article-component .content-wrap { flex-direction: row; }\r\n\t#article-component .content-wrap img { width: 50%; }\r\n\t#article-component .content-wrap .copy-wrap { padding: 72px; width: 696px; }\r\n}\r\n<\/style>\r\n<div class=\"row\" id=\"article-component\">\r\n<div class=\"container\">\r\n<div class=\"row\">\r\n<div class=\"col-xxxs-12 col-md-12 col-lg-12 col-xl-12\">\r\n<div class=\"content-wrap\">\r\n\t<img loading=\"lazy\" decoding=\"async\" src=\"https:\/\/www.americanconference.com\/controlled-substances\/wp-content\/uploads\/sites\/2006\/2026\/09\/750L26_Linkedin_1200x1200_LAB-simple.png\" alt=\"banner\" width=\"576\" height=\"576\">\r\n\t<div class=\"copy-wrap\">\r\n\t\t<h5>New This Year<\/h5>\r\n\t\t<h3>Life Sciences Enforcement Operations LAB: Building the First 72-Hour Response to FDA, DEA, DOJ and State Scrutiny<\/h3>\r\n\t\t<p>This limited-seat, scenario-driven LAB puts legal, compliance, quality, regulatory and investigations leaders inside an escalating life sciences enforcement matter and challenges them to manage the critical first 72 hours. Work through inspections, subpoenas, regulator interactions, employee interviews, document preservation, internal escalation and operational risk while building a practical response playbook you can take back to the office.<\/p>\r\n\t\t<a href=\"https:\/\/www.americanconference.com\/controlled-substances\/workshops\/life-sciences-enforcement-operations-lab\/\" class=\"mainlink\">Learn More<\/a>\r\n\t<\/div>\r\n<\/div>\r\n<\/div>\r\n<\/div>\r\n<\/div>\r\n<\/div>\r\n\r\n\r\n<div class=\"row\" id=\"article-component\">\r\n<div class=\"container\">\r\n<div class=\"row\">\r\n<div class=\"col-xxxs-12 col-md-12 col-lg-12 col-xl-12\">\r\n<div class=\"content-wrap\">\r\n\t<img loading=\"lazy\" decoding=\"async\" src=\"https:\/\/www.americanconference.com\/controlled-substances\/wp-content\/uploads\/sites\/2006\/2026\/04\/750L-WAS-overview-article-feature-companies-confront.jpg\" alt=\"article\" width=\"576\" height=\"576\">\r\n\t<div class=\"copy-wrap\">\r\n\t\t<h5>Featured Article<\/h5>\r\n\t\t<h3>Companies Confront New Challenges in Regulation of Controlled Substances<\/h3>\r\n\t\t<p>Learn more about how manufacturers and distributors of controlled substances can ensure they have strong compliance systems and avoid government enforcement actions.<\/p>\r\n\t\t<a href=\".\/content-hub-gate\/?ct=Companies%20Confront%20New%20Challenges%20in%20Regulation%20of%20Controlled%20Substances&#038;cd=Learn%20more%20about%20how%20manufacturers%20and%20distributors%20of%20controlled%20substances%20can%20ensure%20they%20have%20strong%20compliance%20systems%20and%20avoid%20government%20enforcement%20actions.&#038;cs=article-companies-confront-new-challenges\" style=\"text-decoration: underline;\" class=\"content-link article mainlink\">Read Now<\/a>\r\n\t<\/div>\r\n<\/div>\r\n<\/div>\r\n<\/div>\r\n<\/div>\r\n<\/div>\r\n<!-- #14 ARTICLE END -->\r\n\r\n\r\n\r\n\r\n<!-- #16 WEBINAR RECORDING START -->\r\n<style>\r\n#webinar-component { margin-bottom: var(--fold-component-margin); }\r\n#webinar-component .content-wrap { display: flex; background-color: var(--light-grey); border-radius: 2px; overflow: hidden; padding: 36px; }\r\n#webinar-component .content-wrap p.prefix { color: var(--textcolor-b) !important; text-transform: uppercase; font-size: 12px; line-height: 20px; margin-bottom: 14px !important; }\r\n#webinar-component .content-wrap h3 { margin-bottom: 47px !important; }\r\n<\/style>\r\n<div class=\"row\" id=\"webinar-component\">\r\n<div class=\"container\">\r\n<div class=\"row\">\r\n<div class=\"col-xxxs-12 col-md-12 col-lg-12 col-xl-12\">\r\n<div class=\"content-wrap\">\r\n<div class=\"row\">\r\n\t<div class=\"col-xxxs-12 col-sm-12 col-md-7 col-lg-7 col-xl-7\">\r\n\t\t<p class=\"small prefix\"><strong>Webinar Recording<\/strong><\/p>\r\n\t\t<h3><strong>From Red Flags to FCA Risk: A One Hour Briefing for Controlled Substances Stakeholders<\/strong><\/h3>\r\n\t\t<a href=\".\/content-hub-gate\/?ct=From%20Red%20Flags%20to%20FCA%20Risk%3A%20A%20One%20Hour%20Briefing%20for%20Controlled%20Substances%20Stakeholders&#038;cd=In%20this%20discussion%2C%20the%20three%20co-chairs%20January%E2%80%99s%202026%20Controlled%20Substances%20Summit%20distill%20what%E2%80%99s%20triggering%20investigations%20now%2C%20and%20how%20to%20harden%20policies%2C%20documentation%2C%20and%20data%20practices.&#038;cs=webinar-from-red-flags-to-fca-risks\" style=\"text-decoration: underline;\" class=\"content-link webinar mainlink\">Watch Now<\/a>\r\n\t<\/div>\r\n\t<div class=\"col-xxxs-12 col-sm-12 col-md-5 col-lg-5 col-xl-5\">\r\n\t\t<img loading=\"lazy\" decoding=\"async\" src=\"https:\/\/www.americanconference.com\/controlled-substances\/wp-content\/uploads\/sites\/2006\/2025\/11\/750L26-NYC-Webinar-From-Red-Flags-thumb.jpg\" alt=\"thumb\" width=\"1280\" height=\"720\" \/>\r\n\t<\/div>\r\n<\/div>\r\n<\/div>\r\n<\/div>\r\n<\/div>\r\n<\/div>\r\n<\/div>\r\n<!-- #16 WEBINAR RECORDING END -->\r\n\r\n\r\n\r\n\r\n<!-- #17 TESTIMONIALS START -->\r\n<style>\r\n#testimonials-component { margin: 72px 0 0; }\r\n#testimonials-component h2 { color: var(--textcolor-a); text-align: center; }\r\n#testimonials-component .testimonials-grid { display: grid; grid-template-columns: repeat(3, minmax(0, 1fr)); gap: 48px; max-width: 1200px; margin: 0 auto; }\r\n#testimonials-component .testimonial-card { padding: 0; }\r\n#testimonials-component .testimonial-card .stars { text-align: center; margin-bottom: 24px; color: var(--color-b); }\r\n#testimonials-component .testimonial-card blockquote { margin: 0 0 20px; padding: 0; border: none; text-indent: 2em; font-family: serif; font-style: normal; font-weight: normal; font-size: 18px; line-height: 24px; color: var(--textcolor-a); }\r\n#testimonials-component .testimonial-card cite { display: block; margin: 0; font-style: normal; font-weight: normal; font-size: 12px; line-height: 20px; color: var(--textcolor-c); }\r\n@media (min-width: 320px) { #testimonials-component .testimonials-grid { grid-template-columns: 1fr; } }\r\n@media (min-width: 768px) { #testimonials-component .testimonials-grid { display: grid; grid-template-columns: repeat(3, minmax(0, 1fr)); gap: 48px; max-width: 1200px; margin: 0 auto; } }\r\n<\/style>\r\n<div class=\"row\" id=\"testimonials-component\">\r\n<div class=\"container\">\r\n<div class=\"row\">\r\n<div class=\"col-xxxs-12 col-md-12 col-lg-12 col-xl-12\">\r\n\t<h2>Testimonials<\/h2>\r\n<\/div>\r\n<\/div>\r\n<div class=\"testimonials-grid\">\r\n\r\n\t<div class=\"testimonial-card\">\r\n\t\t<div class=\"stars\">&#9733;&#9733;&#9733;&#9733;&#9733;<\/div>\r\n\t\t<blockquote>\r\n\t\t\t\u201cOur partnership with ACI has been a valuable part of Guidepost Solutions&#8217; business development efforts, and that value flows through to our clients. ACI&#8217;s conferences are consistently well-run and informative, giving our team the chance to both attend and speak alongside other thought leaders. Those exchanges of ideas push our thinking forward and help us grow as practitioners. We&#8217;re proud to sponsor ACI and to be part of a community that takes this work seriously.\u201d\r\n\t\t<\/blockquote>\r\n\t\t<cite>&mdash;Guidepost Solutions<\/cite>\r\n\t<\/div>\r\n\r\n\t<div class=\"testimonial-card\">\r\n\t\t<div class=\"stars\">&#9733;&#9733;&#9733;&#9733;&#9733;<\/div>\r\n\t\t<blockquote>\r\n\t\t\t\u201cThis was one of the better controlled substance conferences since many of the other ones repeat the same topics. This was progressive and relevant.\u201d\r\n\t\t<\/blockquote>\r\n\t\t<cite>&mdash;Ascent Pharmaceuticals<\/cite>\r\n\t<\/div>\r\n\r\n\t<div class=\"testimonial-card\">\r\n\t\t<div class=\"stars\">&#9733;&#9733;&#9733;&#9733;&#9733;<\/div>\r\n\t\t<blockquote>\r\n\t\t\t\u201cThis conference was spot on with the issues we are facing everyday.\u201d\r\n\t\t<\/blockquote>\r\n\t\t<cite>&mdash;Novartis Institutes for Biomedical Research<\/cite>\r\n\t<\/div>\r\n\r\n\t<div class=\"testimonial-card\">\r\n\t\t<div class=\"stars\">&#9733;&#9733;&#9733;&#9733;&#9733;<\/div>\r\n\t\t<blockquote>\r\n\t\t\t\u201cIt was great to hear from current and former industry leaders and experts from DEA, US AG offices, FDA, etc. Hearing about the current events and upcoming trends\/expectations was valuable.\u201d\r\n\t\t<\/blockquote>\r\n\t\t<cite>&mdash;Kroger Health<\/cite>\r\n\t<\/div>\r\n\r\n\t<div class=\"testimonial-card\">\r\n\t\t<div class=\"stars\">&#9733;&#9733;&#9733;&#9733;&#9733;<\/div>\r\n\t\t<blockquote>\r\n\t\t\t\u201cAs the Director of Compliance for IPC, I was extremely pleased with last year\u2019s speakers and the insight they provided into the latest controlled substance regulations.\u201d\r\n\t\t<\/blockquote>\r\n\t\t<cite>&mdash;Independent Pharmacy Cooperative<\/cite>\r\n\t<\/div>\r\n\r\n<\/div>\r\n\r\n<\/div>\r\n<\/div>\r\n<!-- #17 TESTIMONIALS END -->\r\n\r\n\r\n<!-- FOLD END -->\r\n<\/div>\r\n<\/div>","protected":false},"excerpt":{"rendered":"Latest News &amp;&nbsp;Updates NEW THIS YEAR &mdash; Life Sciences Enforcement Operations LAB: Building the First 72-Hour Response to FDA, DEA, DOJ and State Scrutiny February 3, 2027 &bull; 10am&ndash;4pm Learn More Get a Sneak Peek of the 2027 Agenda! View Agenda Preparing for the Next Era of Controlled Substances Regulation, Enforcement, and Compliance The controlled&hellip;","protected":false},"author":14692,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"page-event-overview.php","meta":{"footnotes":""},"class_list":["post-1240","page","type-page","status-publish","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v26.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Overview | Controlled Substances - Regulation, Litigation, and Enforcement<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.americanconference.com\/controlled-substances\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Overview | Controlled Substances - Regulation, Litigation, and Enforcement\" \/>\n<meta property=\"og:description\" content=\"Latest News &amp;&nbsp;Updates NEW THIS YEAR &mdash; Life Sciences Enforcement Operations LAB: Building the First 72-Hour Response to FDA, DEA, DOJ and State Scrutiny February 3, 2027 &bull; 10am&ndash;4pm Learn More Get a Sneak Peek of the 2027 Agenda! View Agenda Preparing for the Next Era of Controlled Substances Regulation, Enforcement, and Compliance The controlled&hellip;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.americanconference.com\/controlled-substances\/\" \/>\n<meta property=\"og:site_name\" content=\"Controlled Substances - Regulation, Litigation, and Enforcement\" \/>\n<meta property=\"article:modified_time\" content=\"2026-10-09T14:52:49+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.americanconference.com\/controlled-substances\/wp-content\/uploads\/sites\/2006\/2025\/07\/750L26_linkedin_general_1200x1200.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"1200\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:image\" content=\"https:\/\/www.americanconference.com\/controlled-substances\/wp-content\/uploads\/sites\/2006\/2022\/11\/750L23_twitter.png\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"7 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.americanconference.com\/controlled-substances\/\",\"url\":\"https:\/\/www.americanconference.com\/controlled-substances\/\",\"name\":\"Overview | Controlled Substances - Regulation, Litigation, and Enforcement\",\"isPartOf\":{\"@id\":\"https:\/\/www.americanconference.com\/controlled-substances\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.americanconference.com\/controlled-substances\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.americanconference.com\/controlled-substances\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.americanconference.com\/controlled-substances\/wp-content\/uploads\/sites\/2006\/2025\/07\/jolie-apicella.png\",\"datePublished\":\"2023-01-10T16:16:25+00:00\",\"dateModified\":\"2026-10-09T14:52:49+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/www.americanconference.com\/controlled-substances\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.americanconference.com\/controlled-substances\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.americanconference.com\/controlled-substances\/#primaryimage\",\"url\":\"https:\/\/www.americanconference.com\/controlled-substances\/wp-content\/uploads\/sites\/2006\/2025\/07\/jolie-apicella.png\",\"contentUrl\":\"https:\/\/www.americanconference.com\/controlled-substances\/wp-content\/uploads\/sites\/2006\/2025\/07\/jolie-apicella.png\",\"width\":200,\"height\":200},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.americanconference.com\/controlled-substances\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.americanconference.com\/controlled-substances\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Overview\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.americanconference.com\/controlled-substances\/#website\",\"url\":\"https:\/\/www.americanconference.com\/controlled-substances\/\",\"name\":\"Controlled Substances - Regulation, Litigation, and Enforcement\",\"description\":\"Template used to create new conference sites\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.americanconference.com\/controlled-substances\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Overview | Controlled Substances - Regulation, Litigation, and Enforcement","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.americanconference.com\/controlled-substances\/","og_locale":"en_US","og_type":"article","og_title":"Overview | Controlled Substances - Regulation, Litigation, and Enforcement","og_description":"Latest News &amp;&nbsp;Updates NEW THIS YEAR &mdash; Life Sciences Enforcement Operations LAB: Building the First 72-Hour Response to FDA, DEA, DOJ and State Scrutiny February 3, 2027 &bull; 10am&ndash;4pm Learn More Get a Sneak Peek of the 2027 Agenda! View Agenda Preparing for the Next Era of Controlled Substances Regulation, Enforcement, and Compliance The controlled&hellip;","og_url":"https:\/\/www.americanconference.com\/controlled-substances\/","og_site_name":"Controlled Substances - Regulation, Litigation, and Enforcement","article_modified_time":"2026-10-09T14:52:49+00:00","og_image":[{"width":1200,"height":1200,"url":"https:\/\/www.americanconference.com\/controlled-substances\/wp-content\/uploads\/sites\/2006\/2025\/07\/750L26_linkedin_general_1200x1200.png","type":"image\/png"}],"twitter_card":"summary_large_image","twitter_image":"https:\/\/www.americanconference.com\/controlled-substances\/wp-content\/uploads\/sites\/2006\/2022\/11\/750L23_twitter.png","twitter_misc":{"Est. reading time":"7 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.americanconference.com\/controlled-substances\/","url":"https:\/\/www.americanconference.com\/controlled-substances\/","name":"Overview | Controlled Substances - Regulation, Litigation, and Enforcement","isPartOf":{"@id":"https:\/\/www.americanconference.com\/controlled-substances\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.americanconference.com\/controlled-substances\/#primaryimage"},"image":{"@id":"https:\/\/www.americanconference.com\/controlled-substances\/#primaryimage"},"thumbnailUrl":"https:\/\/www.americanconference.com\/controlled-substances\/wp-content\/uploads\/sites\/2006\/2025\/07\/jolie-apicella.png","datePublished":"2023-01-10T16:16:25+00:00","dateModified":"2026-10-09T14:52:49+00:00","breadcrumb":{"@id":"https:\/\/www.americanconference.com\/controlled-substances\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.americanconference.com\/controlled-substances\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.americanconference.com\/controlled-substances\/#primaryimage","url":"https:\/\/www.americanconference.com\/controlled-substances\/wp-content\/uploads\/sites\/2006\/2025\/07\/jolie-apicella.png","contentUrl":"https:\/\/www.americanconference.com\/controlled-substances\/wp-content\/uploads\/sites\/2006\/2025\/07\/jolie-apicella.png","width":200,"height":200},{"@type":"BreadcrumbList","@id":"https:\/\/www.americanconference.com\/controlled-substances\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.americanconference.com\/controlled-substances\/"},{"@type":"ListItem","position":2,"name":"Overview"}]},{"@type":"WebSite","@id":"https:\/\/www.americanconference.com\/controlled-substances\/#website","url":"https:\/\/www.americanconference.com\/controlled-substances\/","name":"Controlled Substances - Regulation, Litigation, and Enforcement","description":"Template used to create new conference sites","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.americanconference.com\/controlled-substances\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"_links":{"self":[{"href":"https:\/\/www.americanconference.com\/controlled-substances\/wp-json\/wp\/v2\/pages\/1240","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.americanconference.com\/controlled-substances\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.americanconference.com\/controlled-substances\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.americanconference.com\/controlled-substances\/wp-json\/wp\/v2\/users\/14692"}],"replies":[{"embeddable":true,"href":"https:\/\/www.americanconference.com\/controlled-substances\/wp-json\/wp\/v2\/comments?post=1240"}],"version-history":[{"count":16,"href":"https:\/\/www.americanconference.com\/controlled-substances\/wp-json\/wp\/v2\/pages\/1240\/revisions"}],"predecessor-version":[{"id":2059,"href":"https:\/\/www.americanconference.com\/controlled-substances\/wp-json\/wp\/v2\/pages\/1240\/revisions\/2059"}],"wp:attachment":[{"href":"https:\/\/www.americanconference.com\/controlled-substances\/wp-json\/wp\/v2\/media?parent=1240"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}